Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.

Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.

OBJECTIVE: To assess the efficacy and safety of intravenous administration of golimumab in patients with rheumatoid arthritis (RA). METHODS: Adult patients with RA in whom disease activity was persistent despite treatment with methotrexate (MTX) at a dosage of 15-25 mg/week for > or = 4 week...

Bibliografske podrobnosti
Main Authors:	Kremer, J, Ritchlin, C, Mendelsohn, A, Baker, D, Kim, L, Xu, Z, Han, J, Taylor, P
Format:	Journal article
Jezik:	English
Izdano:	2010

Podobne knjige/članki

Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
od: Taylor, P, et al.
Izdano: (2011)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
od: Natalia Vladimirovna Chichasova
Izdano: (2014-12-01)

Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
od: Fumiko Yamairi, et al.
Izdano: (2020-08-01)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
od: Aaron Broadwell, et al.
Izdano: (2023-03-01)

THE EFFECT OF GOLIMUMAB ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
od: L. A. Knyazeva, et al.
Izdano: (2018-03-01)

Celestina's Age: Is She Forty-Eight?
od: Anne Eesley
Izdano: (2021-01-01)

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
od: Maini, R, et al.
Izdano: (1998)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
od: M. Elaine Husni, et al.
Izdano: (2022-03-01)

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
od: John Tesser, et al.
Izdano: (2019-08-01)

Edible art : forty-eight garnishes for the professional/
od: 230204 Larousse, David Paul
Izdano: (1987)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
od: Proton Rahman, et al.
Izdano: (2020-09-01)

GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
od: Wordsworth, P, et al.
Izdano: (2009)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
od: M. Rossini, et al.
Izdano: (2015-03-01)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
od: Melissa A Michelon, et al.
Izdano: (2010-05-01)

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa
od: Marien Siqueira Soto Lopes, et al.
Izdano: (2013-11-01)

Effects of Eight Weeks of Core Stability Training on Serum level of Progranulin and Tumor Necrosis Factor Alpha in Women with Multiple Sclerosis
od: Maryam Karimi, et al.
Izdano: (2021-01-01)

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
od: Elliott, M, et al.
Izdano: (1994)

GOLIMUMAB, A HUMAN TNF-ALPHA mu ONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF-ALPHA AGENTS (GO-AFTER STUDY)
od: Wordsworth, P, et al.
Izdano: (2009)

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
od: Clifton O. Bingham, et al.
Izdano: (2023-02-01)

Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues
od: N. V. Chichasova
Izdano: (2016-06-01)

Reagan at Reykjavik : forty-eight hours that ended the Cold War /
od: 238191 Adelman, Kenneth L.
Izdano: (2014)

EFFECT OF GOLIMUMAB ON IMMUNOLOGICAL MARKERS FOR BONE METABOLISM AND ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
od: L. A. Knyazeva, et al.
Izdano: (2018-07-01)

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab
od: Ellis LA, et al.
Izdano: (2019-01-01)

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
od: Feldmann, M, et al.
Izdano: (1997)

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
od: Brennan, F, et al.
Izdano: (1995)

Golimumab for the treatment of psoriatic arthritis
od: H Yang, et al.
Izdano: (2011-05-01)

Golimumab Therapy in Ulcerative Colitis
od: Won Moon
Izdano: (2016-02-01)

Golimumab in the treatment of ulcerative colitis
od: Georgina Cunningham, et al.
Izdano: (2019-01-01)

Golimumab for the treatment of ulcerative colitis
od: Löwenberg M, et al.
Izdano: (2014-03-01)

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
od: Manuel Pombo-Suárez, et al.
Izdano: (2023-06-01)

Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial
od: Thomas Daix, et al.
Izdano: (2023-03-01)

Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial
od: Peng Xie, et al.
Izdano: (2024-07-01)

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial
od: Philip Mease, et al.
Izdano: (2020-03-01)

The effect of eight-week yoga training on serum levels of interleukin 6, interleukin 10, tumor necrosis factor alpha and body composition in women with multiple sclerosis
od: Elham Maddah, et al.
Izdano: (2024-08-01)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
od: Maini, R, et al.
Izdano: (1995)

Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
od: Ulfgren, A, et al.
Izdano: (2000)

Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting
od: Seiji Yokoyama, et al.
Izdano: (2022-11-01)

Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis
od: Federica Rivolta, et al.
Izdano: (2023-03-01)

GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS
od: G. V. Lukina, et al.
Izdano: (2015-04-01)

The abilities of golimumab in the therapy of ankylosing spondylitis
od: Sh. F. Erdes
Izdano: (2014-09-01)